Suppr超能文献

ACO 能否准备好为药物使用负责?

Are ACOs Ready to be Accountable for Medication Use?

机构信息

Chief Science Officer, Health Services Research, National Pharmaceutical Council, Washington, DC.

Senior Director, Medication Management, and Managing Principal, Pharmacy Consulting, Healthcare Innovators Collaborative, Premier Healthcare Alliance, Charlotte, North Carolina.

出版信息

J Manag Care Spec Pharm. 2020 Nov;26(11):1446-1451. doi: 10.18553/jmcp.2020.26.11.1446.

Abstract

Accountable care organizations (ACOs) have the potential to lower costs and improve quality through incentives and coordinated care. However, the design brings with it many new challenges. One such challenge is the optimal use of pharmaceuticals. Most ACOs have not yet focused on this integral facet of care, even though medications are a critical component to achieving the lower costs and improved quality that are anticipated with this new model. To evaluate whether ACOs are prepared to maximize the value of medications for achieving quality benchmarks and cost offsets. During the fall of 2012, an electronic readiness self-assessment was developed using a portion of the questions and question methodology from the National Survey of Accountable Care Organizations, along with original questions developed by the authors. The assessment was tested and subsequently revised based on feedback from pilot testing with 5 ACO representatives. The revised assessment was distributed via e-mail to a convenience sample (n=175) of ACO members of the American Medical Group Association, Brookings-Dartmouth ACO Learning Network, and Premier Healthcare Alliance. The self-assessment was completed by 46 ACO representatives (26% response rate). ACOs reported high readiness to manage medications in a few areas, such as transmitting prescriptions electronically (70%), being able to integrate medical and pharmacy data into a single database (54%), and having a formulary in place that encourages generic use when appropriate (50%). However, many areas have substantial room for improvement with few ACOs reporting high readiness. Some notable areas include being able to quantify the cost offsets and hence demonstrate the value of appropriate medication use (7%), notifying a physician when a prescription has been filled (9%), having protocols in place to avoid medication duplication and polypharmacy (17%), and having quality metrics in place for a broad diversity of conditions (22%). Developing the capabilities to support, monitor, and ensure appropriate medication use will be critical to achieve optimal patient outcomes and ACO success. The ACOs surveyed have embarked upon an important journey towards this goal, but critical gaps remain before they can become fully accountable. While many of these organizations have begun adopting health information technologies that allow them to maximize the value of medications for achieving quality outcomes and cost offsets, a significant lag was identified in their inability to use these technologies to their full capacities. In order to provide further guidance, the authors have begun documenting case studies for public release that would provide ACOs with examples of how certain medication issues have been addressed by ACOs or relevant organizations. The authors hope that these case studies will help ACOs optimize the value of pharmaceuticals and achieve the "triple aim" of improving care, health, and cost. There was no outside funding for this study, and the authors report no conflicts of interest related to the article. Concept and design were primarily from Dubois and Kotzbauer, with help from Feldman, Penso, and Westrich. Data collection was done by Feldman, Penso, Pope, and Westrich, and all authors participated in data interpretation. The manuscript was written primarily by Westrich, with help from all other authors, and revision was done primarily by Lustig and Westrich, with help from all other authors.

摘要

责任医疗组织 (ACO) 通过激励措施和协调护理有降低成本和提高质量的潜力。然而,其设计带来了许多新的挑战。其中一个挑战是药品的最佳使用。大多数 ACO 尚未关注这一护理的基本方面,尽管药物是实现该新模式预期的更低成本和更高质量的关键组成部分。评估 ACO 是否准备好最大限度地发挥药物的价值,以实现质量基准和成本抵消。在 2012 年秋季,使用国家责任医疗组织调查的一部分问题和问题方法以及作者开发的原始问题,开发了电子准备情况自我评估。评估根据与 5 名 ACO 代表进行的试点测试的反馈进行了测试和随后的修订。修订后的评估通过电子邮件分发给美国医疗集团协会、布鲁金斯-达特茅斯 ACO 学习网络和 Premier Healthcare Alliance 的 ACO 成员便利样本(n=175)。自我评估由 46 名 ACO 代表完成(26%的回复率)。ACO 报告在一些领域管理药物的准备情况很高,例如电子传输处方(70%)、能够将医疗和药房数据集成到单个数据库中(54%)以及拥有鼓励在适当情况下使用通用药物的处方集(50%)。然而,许多领域有很大的改进空间,很少有 ACO 报告准备情况良好。一些值得注意的领域包括能够量化成本抵消,从而证明适当药物使用的价值(7%)、在处方已填写时通知医生(9%)、制定协议以避免药物重复使用和多种药物治疗(17%)以及为广泛的各种疾病制定质量指标(22%)。开发支持、监测和确保适当药物使用的能力对于实现最佳患者结果和 ACO 成功至关重要。接受调查的 ACO 已经朝着这个目标迈出了重要的一步,但在他们能够完全负责之前,仍然存在关键差距。虽然许多这些组织已经开始采用允许他们最大限度地发挥药物价值以实现质量结果和成本抵消的健康信息技术,但在他们无法充分利用这些技术方面存在重大差距。为了提供进一步的指导,作者已开始记录公开发布的案例研究,为 ACO 提供有关如何解决特定药物问题的示例,这些问题已由 ACO 或相关组织解决。作者希望这些案例研究将帮助 ACO 优化药品的价值,并实现改善护理、健康和成本的“三重目标”。这项研究没有外部资金,作者与文章没有利益冲突。概念和设计主要来自杜波依斯和科茨鲍尔,费尔德曼、彭索、韦斯特里奇提供了帮助。数据收集由费尔德曼、彭索、波普和韦斯特里奇完成,所有作者都参与了数据解释。手稿主要由韦斯特里奇撰写,其他作者提供了帮助,卢斯蒂格和韦斯特里奇主要负责修改,其他作者也提供了帮助。

相似文献

1
Are ACOs Ready to be Accountable for Medication Use?ACO 能否准备好为药物使用负责?
J Manag Care Spec Pharm. 2020 Nov;26(11):1446-1451. doi: 10.18553/jmcp.2020.26.11.1446.
3
Optimization of Medication Use at Accountable Care Organizations.优化问责制医疗组织中的药物使用。
J Manag Care Spec Pharm. 2017 Oct;23(10):1054-1064. doi: 10.18553/jmcp.2017.23.10.1054.

本文引用的文献

4
Patient engagement in health care.患者参与医疗保健。
Health Serv Res. 2011 Apr;46(2):389-93. doi: 10.1111/j.1475-6773.2011.01254.x.
7
The triple aim: care, health, and cost.三重目标:医疗、健康和成本。
Health Aff (Millwood). 2008 May-Jun;27(3):759-69. doi: 10.1377/hlthaff.27.3.759.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验